Introduction
============

Lung cancer is the leading cause of cancer-associated mortality globally and one of the five top causes of years of potential life lost in East Asia, in 2013. Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancers. However, the incidence rates and death rates have declined over the last 20 years ([@b1-ol-0-0-7400],[@b2-ol-0-0-7400]). Due to the advances made in early diagnosis and treatment, the outcome for patients has improved, and this has motivated further research concerning novel targets for the diagnosis and treatment of lung cancer. The disordered metabolism of tumor cells is involved in rapid cell proliferation, maintenance of redox homeostasis and epigenetics ([@b3-ol-0-0-7400],[@b4-ol-0-0-7400]). Interest in this topic has waxed and waned since the observations of Warburg ([@b5-ol-0-0-7400]). In previous years, multiple oncogenes and tumor suppressors have been linked to the regulation of cancer cell metabolism, making this particular topic one of the most intense areas of cancer research ([@b6-ol-0-0-7400]).

Proline is one of the most abundant amino acids in the cellular microenvironment. Proline metabolism and synthesis are associated with the tricarboxylic acid cycle, urea cycle and pentose phosphate pathway. Thus, proline metabolism and synthesis are critically important for tumor cells ([@b7-ol-0-0-7400],[@b8-ol-0-0-7400]). Proline dehydrogenase/proline oxidase (PRODH/POX) catalyzes the first step in proline catabolism, and its function in tumors has attracted attention since it was reported to be a P53-induced gene in tumor cell lines ([@b9-ol-0-0-7400],[@b10-ol-0-0-7400]). PRODH/POX is downregulated in multiple types of human tumor, particularly those of the kidney, stomach, colon and rectum. It functions as a mitochondrial tumor suppressor primarily through inhibiting cell proliferation, inducing apoptosis and suppressing hypoxia-inducible factor 1 signaling ([@b11-ol-0-0-7400]). The function of proline synthesis in cancer, however, remains to be comprehensively understood. Pyrroline-5-carboxylate reductase (PYCR) catalyzes the last step of proline synthesis, and three isozymes are encoded by three human genes. A mutation in PYCR1 was described in patients with autosomal-recessive cutis laxa type 2, indicating a critical function for proline in normal development ([@b12-ol-0-0-7400]). An association between PYCR1 gene expression and breast cancer growth has been reported by a previous study ([@b13-ol-0-0-7400]). These studies indicate that PYCR1 may participate in the process of tumorigenesis.

The aim of the present study was to investigate the function of PYCR1 in lung cancer. PYCR1 expression was detected and compared in lung cancer and its adjacent normal lung tissue. Furthermore, the influence of PYCR1 knockdown on cell proliferation, the cell cycle and apoptosis was investigated in order to explore the function of PYCR1 in the tumorigenesis of lung cancer.

Materials and methods
=====================

### Patients and tissue specimens

Paired NSCLC samples and adjacent normal tissues were obtained from 28 patients who underwent primary surgical resection to treat NSCLC in the Department of Thoracic Surgery, Jinling Hospital, Nanjing University School of Medicine (Nanjing, China) between July 2014 and September 2014. The specimens were collected during surgery and were kept frozen in liquid nitrogen until RNA and protein extraction. In addition, 62 patients with NSCLC with clinicopathological data and follow-up information (61/62) who underwent surgical resection between June 2007 and November 2008 were enrolled, and their paraffin-embedded specimens were collected from the Department of Pathology, Jinling Hospital, for immunohistochemical staining. Follow-up lasted until February 2015, with a median follow-up period of 84.5 months for living patients (range, 75--94 months). None of these patients received chemotherapy or radiotherapy prior to surgery. The present study was reviewed and approved by the Institutional Review Board of Jinling Hospital, and all patients signed an informed consent form prior to undergoing surgery.

### Oncomine^®^ Platform Bioinformatics

The gene search function of Oncomine^®^ Platform ([www.oncomine.org](www.oncomine.org)) was used to analyze the mRNA expression of PYCR1 in NSCLC tissues relative to their normal controls (14). Gene lists based on fold change were obtained from six NSCLC datasets which were named by the first author and numbers of patient as follows: Selamat (116), Su (66), Stearman (39), Hou (156), Beer (96) and Bhattacharjee (203).

### Cell culture

All NSCLC cell lines (A549, SPC-A1, H1703, H1299, PC9, H1915, SK-MES-1) were obtained from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) except for SPC-A1, which was cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% heat-inactivated fetal bovine serum (Hyclone; GE Healthcare, Chicago, IL, USA), 100 U/ml penicillin and 100 mg/ml streptomycin at 37.8°C in a humidified atmosphere containing 5% CO~2~.

### Reverse-transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

Total RNA was extracted from frozen tissues or cultured cells using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocol. Total RNA was reverse transcribed to cDNA using a PrimeScript^™^ RT Master Mix (Perfect Real Time) cDNA synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer\'s protocol. Amplifications were performed in a quantitative real-time PCR machine (Agilent Technologies, Inc., Santa Clara, CA, USA) using SYBR Premix Ex *Taq* (Takara Biotechnology Co., Ltd.). The PCR cycling conditions were conducted as follows: 95°C for 30 sec followed by 40 cycles of 95°C for 5 sec and 60°C for 31 sec. The primer sequences used were as follows: Human β-actin forward, 5′-AGCGAGCATCCCCCAAAGTT-3′; and reverse, 5′-GGGCACGAAGGCTCATCATT-3′ ([@b15-ol-0-0-7400]); human PYCR1 forward, 5′-ACACCCCACAACAAGGAGAC-3′; and reverse, 5′-CTGGAGTGTTGGTCATGCAG-3′ ([@b16-ol-0-0-7400]). All samples were loaded in triplicates. Relative mRNA expression levels were compared via the 2^−ΔΔCq^ method or log-transformed ([@b17-ol-0-0-7400]). The data were analyzed using MxPro qPCR software v1.2 (Agilent Technologies, Inc.).

### Western blot analysis

Total protein was extracted from frozen tissues or cells using RIPA lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) containing a protease inhibitor cocktail (Roche, Basel, Switzerland), at 4°C for 20 min, and centrifuged at 14,000 × g, for 10 min at 4°C. A total of 50 mg of protein (5 mg/µl sourced from the tissues and 2.5 mg/µl sourced from the cells) were separated on 12% SDS-PAGE and blotted onto polyvinylidene fluoride Immobilon-P membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% milk solution for 2 h at room temperature, the membranes were incubated with primary antibodies against PYCR1 (cat. no. ab150347; dilution, 1:1,000; Abcam, Cambridge, MA, USA), β-tubulin (cat. no. 2128; dilution, 1:1,000), cyclin D1 (cat. no. 2978; dilution, 1:1,000), B-cell lymphoma-2 (Bcl-2; cat. no. 2870; dilution, 1:1,000), B-cell lymphoma-extra large (Bcl-xl; cat. no. 2764; dilution, 1:1,000) and BCL2 associated X, apoptosis regulator (Bax; cat. no. 5023; dilution, 1:1,000), all purchased from Cell Signaling Technology, Inc., Danvers, MA, USA, overnight at 4°C. The following day, membranes were probed with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibody (dilution, 1:10,000; cat. no. 7074; Cell Signaling Technology, Inc., Danvers, MA, USA), for 2 h at room temperature. The bands were detected using an Immobilon Western enhanced chemiluminescence HRP substrate kit (cat. no. WBKLS0500; EMD Millipore).

### Immunohistochemistry (IHC)

Sections of formalin-fixed and paraffin-embedded specimens (5-µm thick) were deparaffinized with xylene and rehydrated in a descending ethanol series, 100, 95, 70, 50 and 30%. Heat-induced antigen retrieval was performed by submerging slides in 0.01 mol/l sodium citrate buffer (pH 6.0), and boiling in a microwave oven for 10 min. The sections were treated with 10% normal goat serum (cat. no. ZLI-9021; ZSJQ-BIO, Beijing, China) to block non-specific binding, for 30 min at room temperature. Subsequently, the sections were incubated at 4°C overnight with the aforementioned primary rabbit anti-PYCR1 antibody (1:200; Abcam). The following day, slides were incubated with HRP-conjugated anti-rabbit IgG secondary antibody (cat no. PV-9001; ZSJQ-BIO; dilution, 1:50), at room temperature for 30 min. Finally, the sections were stained using 3,3′-diaminobenzidine for 10 sec-1 min at room temperature, and counterstained with 0.5% hematoxylin for 1 sec at room temperature. Subsequently, slides were dehydrated, and mounted.

IHC staining was independently scored by two pathologists from the Department of Pathology, Jinling Hospital, without any prior knowledge of patient characteristics, and any discrepancy was solved by consensus review. Immunostaining was assessed in five fields of view for each sample, under a light microscope (Carl Zeiss AG, Oberkochen, Germany), at ×200 magnification. The presence of brown staining within cells was considered to be positive staining for PYCR1. Scores representing the percentage of positive cells were as follows: 0, ≤5%; 1, 6--20%; 2, 21--50% and 3, ≥50%. Staining intensity was scored as follows: 0, negative staining; 1, weak staining; 2, moderate staining; and 3, strong staining. The product of the two scores was used as the total staining score. In the following analysis, the expression levels were divided into two groups based on the final scores: Low expression (\<3.5) and high expression (≥3).

### Cell transfection

A549 (2×10^5^ per well) and H1703 (1.5×10^5^ per well) cells were cultured for 1 day until they reached 70--90% confluence. Cells were transfected with PYCR1-specific small interfering (si)RNA or control siRNA using the Lipofectamine 2000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The sequences of the siRNAs used were as follows: Control siRNA sense, 5′-UUCUCCGAACGUGUCACGUTT-3′; and antisense, 5′-ACGUGACACGUUCGGAGAATT-3′; siRNA-PYCR1 sense, 5′-GCCACAGUUUCUGCUCUCATT-3′; and antisense, 5′-UGAGAGCAGAAACUGUGGCTT-3′.

### Cell proliferation assays

Cell proliferation was measured using the CCK-8 cell proliferation kit (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) and 5-ethynyl-2′deoxyuridine (EdU) assay kit (Guangzhou Ribobio Co., Ltd., Guangzhou, China), respectively. For the CCK-8 assay, siRNA-PYCR1 or control siRNA-transfected cells were cultured in a 96-well plate at a density of 3,000 cells per well. CCK-8 solution (20 µl) was added to each well after 0, 24, 48, 72 and 96 h. Cells were incubated at 37°C for 2 h, and the absorbance of samples was recorded at 450 nm using an epoch microplate spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA). All the experiments were performed in triplicate.

For the EdU incorporation assay, dissociated cells were exposed to 50 mM EdU (Guangzhou RiboBio Co., Ltd.) for 2 h at 37°C. Following fixation with 4% formaldehyde for 15 min and permeabilization with 0.5% Triton X-100 for 10 min at room temperature, the cells were incubated with 1X Apollo reaction cocktail (Guangzhou RiboBio Co., Ltd.), 100 µl/well for 30 min. Then, the cells were stained with Hoechst 33342 for 30 min at room temperature and visualized in 3 fields of view/well under a fluorescence microscope (Carl Zeiss). The EdU incorporation rate was expressed as the ratio of EdU-positive cells to total Hoechst 33342-positive cells.

### Clone formation assay

SiRNA-PYCR1 or control siRNA-transfected cells were seeded into a 6-well culture plate at a density of 1,500 cells per dish. Cells were maintained in DMEM containing 10% FBS for 2 weeks and stained with crystal violet for 20 min at room temperature, for colony counting. The visible colonies were manually counted with the naked eye. All experiments were done in triplicate.

### Flow cytometry analysis for cell cycle and apoptosis

Cells, cultured at a density of 1×10^5^/assay, were trypsinized into single cell suspensions and fixed with 70% ethanol for 30 min on ice. Then, the cells were stained with propidium iodide (PI) using the CycleTEST TM PLUS DNA reagent kit (BD Biosciences, San Jose, CA, USA) and analyzed using a FACS Calibur flow cytometer (BD Biosciences) equipped with BD CellQuest software v6.1 (BD Biosciences). For apoptosis analysis, cultured cells were harvested by trypsinization and were double stained with Annexin V-fluorescein isothiocyanate/PI apoptosis detection (BD Biosciences) according to the manufacturer\'s protocol, and analyzed with the aforementioned flow cytometer and software.

### Statistical analysis

Statistical evaluation was performed using SPSS 19.0 software (IBM Corp., Armonk, NY, USA). Two-group comparisons were performed using the Student\'s t-test. χ^2^ and Fisher\'s exact tests were used to analyze the associations between PYCR1 expression and clinicopathological features. Kaplan-Meier survival analyses and Cox\'s proportional hazards models were utilized to determine the association between PYCR1 expression and survival. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Elevated PYCR1 expression in NSCLC tissues and cell lines

To investigate the differences between PYCR1 transcript levels between NSCLC tumor tissues and normal tissues, 28 paired samples of fresh frozen normal tissues and tumor tissues were randomly selected, and the mRNA expression levels examined using RT-qPCR. The results revealed that 16/28 patients (57.1%) demonstrated higher PYCR1 mRNA expression levels in NSCLC specimens compared with normal tissue specimens (≥2-fold change; [Fig. 1A](#f1-ol-0-0-7400){ref-type="fig"}). Overexpression of PYCR1 in lung cancers was further supported by data analysis from the Oncomine platform, which revealed higher PYCR1 mRNA expression levels in lung adenocarcinoma tissues, large cell lung carcinoma tissues and squamous cell lung carcinoma tissues than in normal lung tissues. In 4 paired specimens, PYCR1 was overexpressed in all lung tumor samples compared with normal tissues, as detected by western blot ([Fig. 1B](#f1-ol-0-0-7400){ref-type="fig"}).

To further study whether PYCR1 protein levels were associated with clinicopathological features and prognosis of patients with NSCLC, 62 paraffin-embedded archived NSCLC tissues were examined using immunohistochemical staining. Representative examples of tumor tissues with either strong or weak staining of PYCR1 are presented in [Fig. 1C](#f1-ol-0-0-7400){ref-type="fig"}. The associations between PYCR1 cytoplasmic staining in tumor cells and the clinicopathological features of the 62 patients with NSCLC were further analyzed ([Table I](#tI-ol-0-0-7400){ref-type="table"}). There was no significant association between PYCR1 expression and any clinicopathological characteristic. However, there was a trend towards higher PYCR1 protein expression in tumor specimens with a larger size (\>4 cm). Clinicopathological characteristics and PYCR1 protein expression were also analyzed using Cox\'s univariate and multivariate hazard regression models to evaluate whether high PYCR1 expression was an independent risk factor of poor prognosis ([Table II](#tII-ol-0-0-7400){ref-type="table"}). Kaplan-Meier analysis demonstrated that poor overall survival was associated with lymph node metastasis (P=0.010), tumor-node-metastasis (TNM) stage (P=0.010) and PYCR1 expression ([Fig. 1D](#f1-ol-0-0-7400){ref-type="fig"}; P=0.01). For multivariate survival analysis, TNM stage was associated with overall patient survival \[hazard ratio (HR): 1.926, 95% confidence interval (CI): 1.149--3.227, P=0.013\]. High PYCR1 protein expression was also revealed to be an independent risk factor for poor prognosis (HR: 2.48, 95% CI: 1.164--5.286, P=0.019).

In addition, the mRNA and protein levels of PYCR1 were examined in seven NSCLC cell lines by qPCR and western blotting, respectively ([Fig. 1E and F](#f1-ol-0-0-7400){ref-type="fig"}). The results demonstrated that PYCR1 expression level is highly variable in NSCLC cell lines. According to the results, two NSCLC cell lines with high PYCR1 expression (SPC-A1 and H1703) were selected to perform further *in vitro* investigations.

### Knockdown of PYCR1 expression in NSCLC cells suppresses cell proliferation in vitro

As demonstrated by the aforementioned results, tumors with a larger size tended to have relatively high PYCR1 expression, and overexpression of PYCR1 may be involved in survival. Therefore, the influence of PYCR1 expression on the proliferation of human NSCLC cells was studied. SiRNA was used to specifically knock down PYCR1 expression in SPC-A1 and H1703 cells ([Fig. 2A and B](#f2-ol-0-0-7400){ref-type="fig"}). PYCR1 knockdown reduced SPC-A1 and H1703 cell proliferation, as assessed using a CCK-8 cell proliferation kit ([Fig. 2C and D](#f2-ol-0-0-7400){ref-type="fig"}). The colony-forming ability of the population was also significantly attenuated following knockdown of PYCR1 ([Fig. 2E and F](#f2-ol-0-0-7400){ref-type="fig"}). In addition, EdU incorporation assays were performed to explore the effect of PYCR1 knockdown on DNA replication. Following transfection with siRNA-PYCR1, the percentage of EdU-positive cells was decreased by 21% in SPC-A1 and 71% in H1703 cells ([Fig. 2G and H](#f2-ol-0-0-7400){ref-type="fig"}). These data revealed that PYCR1 is involved in NSCLC cell proliferation.

### Silencing of PYCR1 induces cell cycle arrest and apoptosis

To further examine the function of PYCR1 knockdown in cell cycle and apoptosis, the cell cycle and apoptosis were analyzed in siRNA-PYCR1 or control siRNA-transfected SPC-A1 and H1703 cells using flow cytometry. In si-PYCR1-transfected SPC-A1 cells, the proportion of cells in the G1 phase increased by 14.6% and the proportion of cells in S phase decreased by 21.6% ([Fig. 3A and B](#f3-ol-0-0-7400){ref-type="fig"}). The altered proportion of G1 and S phase cells was more apparent in siRNA-PYCR1-transfected H1703 cells ([Fig. 3A and C](#f3-ol-0-0-7400){ref-type="fig"}). PYCR1 knockdown also induced apoptosis of SPC-A1 cells, in particular late apoptosis ([Fig. 3D and E](#f3-ol-0-0-7400){ref-type="fig"}). In H1703 cells, although there was no significant difference in the total apoptosis rate between si-PYCR1-transfected cells and control cells, the late apoptosis rate was increased following PYCR1 silencing ([Fig. 3D and F](#f3-ol-0-0-7400){ref-type="fig"}). Taken together, these results demonstrated that the loss of PYCR1 results in the arrest of the cell cycle in the G1 phase and the induction of apoptosis in NSCLC cells.

### PYCR1 promotes the cell cycle and inhibits apoptosis through regulating cyclin D1, Bcl-2 and Bcl-xl expression

In order to investigate the molecular mechanism underlying the influence of PYCR1 on the cell cycle and apoptosis in NSCLC, key associated regulators were focused on. The cyclin D family are a group of closely related G1 cyclins, and of these cyclin D1 exhibits a more widespread function in human cancers compared with others ([@b18-ol-0-0-7400]). Thus, it was hypothesized that PYCR1 may promote the cell cycle from the G1 phase into the S phase by regulating the expression of cyclin D1. To test this hypothesis, the expression levels of cyclin D1 following PYCR1 silencing were examined by western blot. The results revealed a significant decrease of cyclin D1 expression in siRNA-PYCR1-transfected SPC-A1 and H1703 cells ([Fig. 4A and B](#f4-ol-0-0-7400){ref-type="fig"}).

As for apoptosis, the Bcl-2 family is essential to mitochondrial-controlled apoptosis. As PYCR1 is located on the surface of mitochondrion ([@b19-ol-0-0-7400]), it was hypothesized that PYCR1 may inhibit apoptosis through its connection to the Bcl-2 family. The results of the present study demonstrated that, following PYCR1 knockdown, Bcl-2 expression levels were significantly decreased in SPC-A1 and H1703 cells ([Fig. 4A and C](#f4-ol-0-0-7400){ref-type="fig"}). There was also a decline in Bcl-xl expression in the two cell lines ([Fig. 4A and D](#f4-ol-0-0-7400){ref-type="fig"}). The Bcl-2/Bax ratio was also decreased, although Bax expression was not affected by the knockdown of PYCR1 ([Fig. 4A, E and F](#f4-ol-0-0-7400){ref-type="fig"}).

Discussion
==========

Disordered glutamine metabolism is involved in lung cancer progression, and has been under intense study to search for promising anticancer therapeutic targets ([@b20-ol-0-0-7400]). Glutamate is a source of proline synthesis, and this relationship drew the attention of our group to the potential function of proline synthesis in lung cancer. Pyrroline-5-carboxylate (P5C) is an intermediate produced from glutamate by P5C synthase, or from ornithine by ornithine aminotransferase in proline synthesis pathways, and this is then converted to proline through PYCR. Of the three known isozymes of PYCR, PYCR1 is primarily involved in the conversion of glutamate to proline in human melanoma cells ([@b21-ol-0-0-7400]). A DNA microarray analysis of prostate cancer in 2002 revealed that the expression levels of PYCR1 were significantly increased in prostate cancer ([@b22-ol-0-0-7400]). The results of the present study demonstrated that PYCR1 is overexpressed in human NSCLC, as detected by RT-qPCR and western blot. Then, by analyzing the clinical significance of PYCR1 expression, it was revealed that in NSCLC tumors with dimensions \>4 cm, PYCR1 expression was higher than those with smaller dimensions (66.7% vs. 45.7%). Following multivariate survival analysis, high PYCR1 expression was revealed to be an independent risk factor for poor overall survival, as well as higher TNM stage.

The involvement of PYCR1 in the proliferation and apoptosis of NSCLC cell lines was also investigated. The results indicated that silencing PYCR1 decreased cell proliferation, resulted in cell cycle arrest at the G1 phase and induced apoptosis. The different medium used for culturing SPC-A1 and H1703 did not alter the effect of PYCR1 on proliferation and apoptosis. H1703 cells were cultured in RPMI-1640 with 0.1 mM proline, while SPC-A1 cells were cultured in DMEM without proline. The similar results in the two cell lines may suggest that the influence of PYCR1 knockdown was not mitigated even with proline at a concentration usually used for essential amino acids (0.1 mM). Possemato *et al* ([@b13-ol-0-0-7400]) revealed that knockdown of PYCR1 reduced tumor formation in breast cancer cell lines. A previous study also confirmed the results of the present study: Silencing of aldehyde dehydrogenase 18 family member A1 (P5CS), PYCR1, 2 and L may decrease tumor cell proliferation in several cancer cell lines, including one NSCLC cell line, PC9 ([@b23-ol-0-0-7400]). However, PYCR1 knockdown did not affect cell cycle and apoptosis in PC9 cells in this study, which is incompatible with the results of the present study. The discordance may be because the expression levels of PYCR1 were decreased in PC9 cells compared with SPC-A1 and H1703 cells, as demonstrated in [Fig. 1E and F](#f1-ol-0-0-7400){ref-type="fig"}. The variation in PYCR1 expression across different cell lines may cause differential results in *in vitro* studies. Repeated studies should be performed in more NSCLC cell lines to confirm the involvement of PYCR1 in the cell cycle and apoptosis in this type of cancer.

The oncogenic transcription factor MYC proto-oncogene, bHLH transcription factor (MYC) is involved in cell proliferation, most notably by targeting G1-specific cyclin-dependent kinases, and it is also associated with apoptosis control ([@b24-ol-0-0-7400],[@b25-ol-0-0-7400]). MYC stimulates mitochondrial biogenesis, which may be important in terms of cell cycle promotion, by helping prepare for cell division ([@b26-ol-0-0-7400]). MYC promotes proline synthesis from glutamine to proline through increasing the expression of glutaminase, P5CS, and PYCR1. It also inhibits the expression of POX/PRODH and thereby inhibits its function, which is to suppress cell growth and induce apoptosis ([@b9-ol-0-0-7400],[@b27-ol-0-0-7400]). Thus, the proline metabolism enzymes PYCR1 and POX/PRODH may contribute, at least in part, to the effect of MYC on cell growth and apoptosis.

The signaling pathway through which PYCR1 promotes cell proliferation and inhibits apoptosis is still unknown. Cyclin D1 is a key regulator of the G1/S checkpoints and forms a complex with cyclin dependent kinase (CDK) 4/6 ([@b28-ol-0-0-7400]). Cyclin D1 is also involved in the regulation of apoptosis, and whether it induces or inhibits apoptosis depends on the cell type, its expression level and the growth conditions ([@b29-ol-0-0-7400]). Due to its involvement in controlling the cell cycle and apoptosis, as well as in lung cancer pathogenesis ([@b30-ol-0-0-7400]), cyclin D1 expression was detected in siRNA-transfected SPC-A1 and H1703 cells and was revealed to be significantly decreased compared with control cells. In addition, overexpression of cyclin D1 resulted in resistance to cisplatin-mediated apoptosis via the maintenance of Bcl-2 and Bcl-xl protein levels in an ela-myc transgene-expressing pancreatic tumor cell line ([@b31-ol-0-0-7400]). Bcl-2 family members are critical regulators of the mitochondrial apoptotic pathway through the balance of and competitive dimerization between the anti-apoptotic members, including Bcl-2 and Bcl-xl, and pro-apoptotic members, including Bax and Bcl-2 antagonist/killer 1 ([@b32-ol-0-0-7400]). High expression of Bcl-2 is associated with an improved outcome in patients with NSCLC with a non-squamous histology, which suggests its involvement in NSCLC ([@b33-ol-0-0-7400]). In the present study, Bcl-2 and Bcl-xl expression, as well as the ratio of Bcl-2/Bax, were revealed to be downregulated following PYCR1 silencing. Taken together, these studies suggested that PYCR1 may promote tumor cell growth by regulating cyclin D1, Bcl-2 and Bcl-xl. Nevertheless, whether the downregulation of Bcl-2 and Bcl-xl was directly caused by PYCR1 or through the low expression of cyclin D1 is worth further research.

In conclusion, the results of the present study demonstrated that PYCR1 is overexpressed in NSCLC, and its high expression is an independent risk factor for poor prognosis. PYCR1 may be a key promoter of tumor cell proliferation. In the future, these data should be expanded upon using *in vivo* models to further elucidate the involvement of PYCR1 in tumorigenesis.
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![PYCR1 is overexpressed in patients with NSCLC, and high PYCR1 expression is associated with poor prognosis. (A) Log^2^ relative PYCR1 transcript levels in 28 clinical specimens, as analyzed by qPCR. PYCR1 mRNA expression levels were increased in the tumor tissues compared with normal tissues. (B) PYCR1 protein expression levels in the paired NSCLC and normal tissues were detected by western blot. (C) Representative examples of PYCR1 expression in tumor tissues as examined by immunohistochemistry: The upper panel depicts strong PYCR1 staining, and the lower panel weak PYCR1 staining. (D) Kaplan-Meier survival analysis of PYCR1 expression in 61 patients with NSCLC. PYCR1 (E) protein and (F) mRNA transcript expression profiles in 7 NSCLC cell lines were analyzed by qPCR and western blotting, respectively. The mRNA expression levels in NSCLC cell lines were compared with those in H1703. PYCR1, pyrroline-5-carboxylate reductase 1; NSCLC, non small cell lung cancer; qPCR, quantitative polymerase chain reaction; T, Tumor; N, Normal.](ol-15-01-0731-g00){#f1-ol-0-0-7400}

![PYCR1 silencing inhibits non small cell lung cancer cell proliferation. (A) Western blot and (B) quantitative polymerase chain reaction analysis of PYCR1 knockdown in SPC-A1 and H1703 cells. Cell proliferation, as detected using Cell Counting Kit-8, demonstrated a significant decrease in (C) SPC-A1 and (D) H1703 cells following PYCR1 silencing. (E) The colony-forming ability of the population was analyzed in siRNA-PYCR1 or siRNA-NC-transfected SPC-A1 and H1703 cells, with (F) quantification. (G) EdU incorporation assays was performed to examine the effect of PYCR1 knockdown on cell proliferation in SPC-A1 and H1703 cells, with (H) quantification. The EdU incorporation rate represents the ratio of EdU-positive cells to total Hoechst 33342-positive cells. The data are expressed as the mean ± standard error of the mean of three independent experiments. Student\'s t-test was used to assess significance. \*P\<0.05 and \*\*P\<0.01 vs. siRNA-NC. PYCR1, pyrroline-5-carboxylate reductase 1; siRNA, small interfering RNA, NC, negative control; EdU, 5-ethynyl-2′deoxyuridine.](ol-15-01-0731-g01){#f2-ol-0-0-7400}

![PYCR1 knockdown induces cell cycle arrest and apoptosis. (A) Cell cycle of siRNA-PYCR1 or siRNA-NC-transfected SPC-A1 and H1703 cells was examined by flow cytometry, with quantification for (B) SPC-A1 and (C) H1703 cells. (D) The percentage of apoptotic cells was detected by flow cytometry, with quantification for (E) SPC-A1 and (F) H1703 cells. The data are expressed as the mean ± standard error of the mean of three independent experiments. Student\'s t-test was used to assess significance. \*P\<0.05 and \*\*P\<0.01 vs. siRNA-NC. PYCR1, pyrroline-5-carboxylate reductase 1; siRNA, small interfering RNA, NC, negative control; PI, propidium iodide.](ol-15-01-0731-g02){#f3-ol-0-0-7400}

![Cyclin D1, Bcl-2 and Bcl-xl were downregulated by the knockdown of PYCR1. (A) Protein expression levels were assessed using western blot analysis following silencing of PYCR1. Quantification was performed for (B) cyclin D1, (C) Bcl-2, (D) Bcl-xl, (E) Bax and (F) the Bcl-2/Bax ratio. β-tublin was used as an internal control. The data are expressed as the mean ± standard error of the mean of three independent experiments. Student\'s t-test was used to assess significance. \*P\<0.05 and \*\*P\<0.01 vs. siRNA-NC. Bcl-2, B-cell lymphoma-2; Bcl-xl, B-cell lymphoma-extra large; PYCR1, pyrroline-5-carboxylate reductase 1; Bax, BCL2 associated X, apoptosis regulator; siRNA, small interfering RNA; NC, negative control.](ol-15-01-0731-g03){#f4-ol-0-0-7400}

###### 

Associations between PYCR1 expression and various clinicopathologic features of 62 patients with non small cell lung cancer.

                                                              PYCR1 expression        
  ------------------------------------------------------ ---- ------------------ ---- -------
  Age at diagnosis, years                                                             
    \<60                                                 24   13                 11   0.933
    ≥60                                                  38   21                 17   
  Sex                                                                                 
    Male                                                 52   30                 22   0.737
    Female                                               11   6                  5    
  Histological type                                                                   
    AC                                                   27   17                 10   0.365
    SCC                                                  25   11                 14   
    Other^[b](#tfn2-ol-0-0-7400){ref-type="table-fn"}^   10   6                  4    
  Tumor differentiation                                                               
    Well, moderate                                       37   22                 15   0.374
    Poor                                                 25   12                 13   
  Tumor size                                                                          
    ≤4 cm                                                35   16                 19   0.100
    \>4 cm                                               27   18                 9    
  Lymph node metastasis                                                               
    Absent                                               37   19                 18   0.502
    Present                                              25   15                 10   
  TNM stage                                                                           
    I                                                    20   9                  11   0.560
    II                                                   25   15                 10   
    III                                                  17   10                 7    

Significance was determined using the χ^2^ test.

Other types of non small cell lung cancer included 8 cases of adenosquamous carcinoma, 1 case of large cell lung cancer and 1 cause of mucoepidermoid carcinoma. PYCR1, pyrroline-5-carboxylate reductase 1; AC, adenocarcinomas; SCC, squamous cell carcinomas; TNM, tumor-node-metastasis.

###### 

Univariate and multivariate analysis of prognostic factors in 61 patients with non small cell lung cancer.

                                                         Univariate analysis^[a](#tfn3-ol-0-0-7400){ref-type="table-fn"}^   Multivariate analysis^[b](#tfn4-ol-0-0-7400){ref-type="table-fn"}^                                  
  ------------------------------------------------------ ------------------------------------------------------------------ -------------------------------------------------------------------- ------- ---------------------- -------
  Age at diagnosis, years                                                                                                                                                                        0.794                          
    \<60                                                 24                                                                 64.04                                                                                               
    ≥60                                                  37                                                                 62.78                                                                                               
  Sex                                                                                                                                                                                            0.129                          
    Male                                                 51                                                                 65.44                                                                                               
    Female                                               10                                                                 51.50                                                                                               
  Histological type                                                                                                                                                                              0.447                          
    AC                                                   27                                                                 65.60                                                                                               
    SCC                                                  24                                                                 63.63                                                                                               
    Other^[c](#tfn5-ol-0-0-7400){ref-type="table-fn"}^   10                                                                 54.70                                                                                               
  Tumor differentiation                                                                                                                                                                          0.445                          
    Well, moderate                                       36                                                                 60.72                                                                                               
    Poor                                                 25                                                                 66.96                                                                                               
  Tumor size                                                                                                                                                                                     0.672                          
    ≤4 cm                                                35                                                                 62.94                                                                                               
    \>4 cm                                               26                                                                 62.46                                                                                               
  Lymph node metastasis                                                                                                                                                                          0.010   1.060 (0.461--2.439)   0.890
    Absent                                               37                                                                 70.61                                                                                               
    Present                                              24                                                                 52.52                                                                                               
  TNM stage                                                                                                                                                                                      0.010   1.926 (1.149--3.227)   0.013
    I                                                    20                                                                 74.80                                                                                               
    II                                                   24                                                                 59.17                                                                                               
    III                                                  17                                                                 53.82                                                                                               
  PYCR1 expression                                                                                                                                                                               0.011   2.480 (1.164--5.286)   0.019
    High                                                 33                                                                 55.49                                                                                               
    Low                                                  28                                                                 72.25                                                                                               

Significance was determined using the log-rank test.

Significance was determined using the Cox regression model

Other kinds of NSCLC included 8 cases of adenosquamous carcinoma, 1 case of large cell lung cancer and 1 case of mucoepidermoid carcinoma. HR, hazards ratio; CI, confidence interval; PYCR1, pyrroline-5-carboxylate reductase 1; AC, adenocarcinomas; SCC, squamous cell carcinomas; TNM, tumor-node-metastasis.
